3D Medicines (Sichuan) Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2016-03-16

Employees: -

Market Cap: -

Website

Clinical Trials

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: KN035

First Posted Date: 2016-07-11

Last Posted Date: 2021-06-02

Lead Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT02827968

Locations: 🇺🇸
Horizon Oncology Research, INC, Lafayette, Indiana, United States
🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy